BRIEF-Array Biopharma presents full results from Phase 3 NEMO study

* Study found binimetinib significantly extended median progression-free survival, at 2.8 months, versus 1.5 months observed with dacarbazine
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.